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Introduction
Valproic acid is used widely in children and adults for
seizure control, and is considered the most well-tolerated
antiepileptic drug. The most common hematologic ad-
verse reaction of valproic acid is thrombocytopenia,
which is considered to be associated with antibody-
mediated platelet destruction. In recent years, a few
cases of valproic acid-induced neutropenia or leukope-
nia have been reported, some caused by a concomi-
tant use of valproic acid and another drug1, while others
were caused by valproic acid only. We report a case of
an intracerebral hemorrhage patient, who used valproic
acid to treat a complication of surgery, and then suf-
fered from severe agranulocytosis.
Case Report
A 75-year-old man was admitted unconscious to the
emergency department. His relatives said he had drunk
a lot of alcohol the night before and had vomited once.
Brain computed tomography was arranged, and the
result showed right-sided intracerebral hemorrhage
with mid-line shift. The patient was intubated urgently
and sent to the operation room for surgery. After sur-
gery, he was admitted to the intensive care unit for fur-
ther treatment. Unfortunately, he had a seizure the
next day and started using valproic acid 600 mg twice a
day to treat this complication. He also suffered from
an episode of severe sepsis. Antibiotic treatment brought
his infection under control. He underwent trache-
ostomy 4 weeks after admission because of respiratory
failure and was then transferred to the respiratory
care center. When the patient’s condition was stable,
he was discharged 9 weeks 4 days after admission. The
last time blood was examined during hospitalization
was 1 week prior to the discharge, and the results proved
normal (hemoglobin [Hb] 12.8 g/dL, white blood cell
count [WBC] 6,100/μL, neutrophils 62.1%). He contin-
ued to use valproic acid.
The patient went to the emergency department
again 10 days after discharge. He complained of diar-
rhea and fever lasting more than 6 days. His blood
examination showed severe agranulocytosis (Hb
11.3 g/dL, WBC 1,700/μL, neutrophils 1%) with normal
liver function. Because of the impression of agranu-
locytosis and neutropenic fever, he was admitted to
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the ward and started taking empirical broad-spectrum
antibiotics. Valproic acid-induced agranulocytosis was
highly suspected, so the doctor stopped valproic acid
the next day and, instead, began prescribing granulo-
cyte colony-stimulating factor 150 μg daily that same
day. His WBC fell to the lowest level later that day 
with mild anemia and a normal platelet count (WBC
1,000/μL, neutrophils 0%, Hb 9.6 g/dL, platelet count
200,000/μL). Bone marrow biopsy and aspiration were
done 4 days later, and the results showed maturation
arrest of the myeloid series, with few segmented or
band WBC, and an increased eosinophil series, which
is clinically compatible with drug-induced agranulocy-
tosis. After the valproic acid treatment was stopped
and granulocyte colony-stimulating factor was admin-
istered, the patient’s WBC and neutrophils increased
to the normal range within 2 weeks. The Table shows
the patient’s laboratory data.
The patient’s blood and pus culture revealed Acine-
tobacter baumannii and methicillin-resistant coagulase-
negative staphylococci infection. While under antibiotic
treatment, his condition improved gradually. During
his period of admission, the patient did not have 
a seizure. When his WBC returned to normal and his
infection was also controlled, he was discharged 
7 weeks 2 days after the second admission. At the time
of writing, he did not use any other antiepileptic drug
and his condition and blood count data remained
normal.
Discussion
Immune-mediated destruction of neutrophils and direct
toxic effects on bone marrow are considered as the two
mechanisms of drug-induced agranulocytosis or neu-
tropenia. Immune forms usually happen days to weeks
after starting the drug, while toxic forms may be delayed
for months2. The mechanism of valproic acid-induced
leukopenia is still unclear, and immunofluorescence
studies failed to find antibodies against granulocytes3. 
Valproic acid-induced neutropenia or agranulocy-
tosis is rare, and the phenomenon seems to be tran-
sient4. O’Connor and colleagues5 have evaluated the
mechanisms of antiepileptic drug-related chronic leu-
kopenia, and suggested a continuation of therapy when
the patient’s bone marrow is normal, leukopenia is sta-
ble and absolute neutrophil count is normal. Another
case reported that a patient’s neutrophil count fell, and
recovered without stopping or changing the dosage of
valproic acid, but 2 months later, severe neutropenia was
noted. Valproic acid was stopped, and the neutrophil
count then returned to normal6. Our patient was dis-
covered to have severe agranulocytosis 2.5 months after
taking valproic acid. According to previous studies, the
mechanism of valproic acid-induced agranulocytosis
may have a direct toxic effect on bone marrow. However,
some cases occurred within a few days,7 while some
occurred after 1 month8. These cases demonstrate that
the phenomenon of valproic acid-induced neutropenia
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Table. Patient blood analysis
First admission Second admission
1 week 
Day 1 Day 1 Day 2 Day 5 Day 6 Day 9 Day 15 Day 19prior to 
discharge
Hemoglobin (g/dL) 12.8 11.3 9.6 10.2 10.3 12 12
Hematocrit  (%) 35.7 31.9 27.3 29.6 28.9 34.4 34.5
Red blood cells  (× 106/μL) 3.26
White blood cells (× 103/μL) 6.1 1.7 1.2 1.0 1.3 1.4 2.6 3.0 5.0
Neutrophils (%) 62.1 1 0 0 1 15 32 65 76.1
Eosinophils (%) 0.5 0 8 0 0 0 2 1 0.2
Basophils (%) 0.4 0 2 0 0 0 0 2 0.8
Monocytes (%) 7.6 2 5 0 17 17 10 7 2.9
Lymphocytes (%) 29.4 93 85 89 77 64 52 23 20
Platelets (× 103/μL) 200 222 298 310 146
may vary among patients. Because the time between
the ingestion of drugs and the onset of agranulocytosis
seems to be unpredictable and the symptoms usually
go unnoticed, regular blood examinations should be
considered. 
Watts et al.9 presented a case of valproic acid-induced
severe anemia and mild neutropenia, and evaluated
the correlation between the dosage and bone marrow
suppression. The result indicated that the inhibition of
bone marrow by valproic acid is dose-dependent. The
valproic acid level may be normal or lower than the ther-
apeutic range when neutropenia occurs8. Our patient’s
valproic acid level was not sampled the next day after
the second admission, so we do not know whether the
patient’s valproic acid level was high or within the
therapeutic range.
A cohort study investigated the frequency of a severe
decrease in blood cell count in patients taking anti-
epileptic drugs10. The analyses showed that patients
older than 60 years had a higher rate of developing a
reduction in blood cells, and the rate was not different
among various antiepileptic drugs. Another retrospec-
tive study reviewed charts of 35 elderly inpatients who
received valproic acid treatment, and showed that val-
proic acid was well tolerated except for one patient who
experienced transient leukopenia4. The safety of val-
proic acid in elderly patients needs to be confirmed in
more studies, and close monitoring may be necessary in
the elderly population.
Our patient was not taking any medication other
than valproic acid and lansoprazole when agranulocy-
tosis occurred. He continued to use lansoprazole with-
out any adverse reaction, so we excluded it as a possible
cause. Use of the Naranjo adverse drug reaction prob-
ability scale indicated that valproic acid was the prob-
able cause (score of 7)11. 
The adverse effect of valproic acid which is of most
concern to doctors is hepatotoxicity. The case we report
here had normal liver function but developed severe
agranulocytosis, which resulted in sepsis. Compared
with other antiepileptic drugs, valproic acid has fewer
adverse effects, but this experience shows us that pa-
tients who take valproic acid may need regular com-
plete blood count checks in addition to their liver
function tests, most importantly in the first 3 months
of their treatment.
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